Insulin slowed down, 6-APA positives reflected. Maintain HOLD. Earnings improved but potential yet to be released: Maintain BUY Virscend Education Interim Results Concerns about Q2 results put to rest. Optics business development will trigger a further re-rating. NEED MORE CONCRETE ACTION TO UNLOCK VALUE Lipusu looking gloomy. Execution in doubt. Downgrade to SELL. Weak 1H17 Results Due to Unfavourable Market Conditions 1H 2017 Results Presentation Key Takeaways. Vietnam operation will have a positive impact. Weaker-than-expected 1H17 results, but recovery expected. Maintain HOLD. Argentina credit: Aim higher